Once-daily tx promising in HCV, HIV coinfection
Simeprevir plus pegylated interferon and ribavirin promising in previously untreated patients with hepatitis C and HIV coinfection.
Diagnosis & Disease Information
Oral dual therapy effective for HCV genotype 1b
LEAGUE-1 study findings on a dual oral hepatitis C virus therapy consisting of daclatasvir and simeprevir, without interferon or ribavirin, are encouraging.
Interferon-free regimen effective in HCV, HIV coinfection
Rates of sustained virologic response ranged from 70% to 90% among patients with HCV and HIV coinfection in the PHOTON-1 study.
Novel triple-drug HCV combo achieves high SVR
Direct-acting investigational “three-D” combination therapy achieves more than 99% sustained virologic response in patients hepatitis C genotype 1b.
Shorter HCV treatment strategy yields benefits
A six-week combination regimen appeared to be as effective as 12 weeks of therapy for patients with hepatitis C virus infections.
- Loading...
Loading...
Next post in Web Exclusives
Loading... 
Loading...